# US 2021/0172965 A1 · Method for measuring and managing red blood cell omega-3 fatty acid docosahexaenoic acid level in human females to support a term pregnancy and reduce risk of spontaneous preterm birth

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0172965 A1
- Document ID: US20210172965A1
- Status: Published application
- Kind: A1
- Application number: 16/705,925
- Filed: 2019-12-06
- Published: 2021-06-10
- Earliest claimed: 2019-12-06
- Assignees: Omegaquant Analytics, LLC
- Applicants: Omegaquant Analytics, LLC
- Inventors: William Stephen HARRIS; Kristina Harris Jackson
- Web page: https://patentgrep.com/patent/US20210172965A1

## CPC

- G01N 33/80: involving blood groups or blood types {or red blood cells (white blood cells G01N33/56972)}
- A23L 33/12: Fatty acids or derivatives thereof
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- G01N 2800/368: Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

A method for measuring and managing DHA levels in a pregnant woman to substantially reduce risk of spontaneous preterm birth, including: determining the blood level of DHA in the pregnant woman at or about the end of the first trimester or beginning of the second trimester, the DHA level being a first comparator; determining level of DHA in at least one pregnant subject at least one predetermined period, where the at least one pregnant subject having achieved a term pregnancy, and where the level of DHA at the at least one predetermined period being at least a second comparator; comparing the level of DHA in the first and at least second comparator; and when the difference between the first and the at least second comparator is greater than a predetermined value, administering to the subject a therapeutically effective amount of DHA to reduce pathology relating to spontaneous preterm birth.

## Claims

### Claim 1

A method for managing and controlling DHA levels in a pregnant subject comprising the steps of:
a. collecting a blood sample from a pregnant woman;
b. analysing the blood sample for a red blood cell (RBC) DHA level; and
c. comparing the analysed red blood cell (RBC) DHA level to a predetermined acceptable DHA level at that period in the term of the pregnancy;
wherein an analysed red blood cell (RBC) DHA level less than the predetermined acceptable DHA level indicates an increased risk for preterm birth.

### Claim 2 (depends on 1)

The method according to claim 1 includes the step of:
d. wherein the DHA levels in a pregnant woman are adapted to aid lowering of the risk of pre-term birth.

### Claim 3 (depends on 1)

The method according to claim 1 including the step of:
e. wherein the DHA levels in a pregnant woman are monitored by undertaking at least steps of claim a.-c. at one or more different stages in the pregnancy term and the prenatal docosahexaenoic acid (DHA) levels are adapted to aid lowering of the risk of pre-term birth.

### Claim 4 (depends on 1)

The method according to claim 1 wherein the step of collecting of the blood sample uses a dried blood spot (DBS) to provide a (DBS) DHA level to assess the red blood cell (RBC) DHA level wherein the dried blood spot (DBS) analysis has an improved viable term for assessment than a direct red blood cell (RBC) DHA.

### Claim 5 (depends on 1)

The method according to claim 1 wherein the improved viable term for assessment using the dried blood spot (DBS) analysis is improved over a direct red blood cell (RBC) DHA by:
a. Extended available assessment time;
b. Reduced temperature degradation;
c. Lessening of temperature control.

### Claim 6 (depends on 1)

The method according to claim 1 wherein the step of analysing the blood sample for a red blood cell (RBC) DHA level uses a predetermined ratio of the (DBS) DHA level to provide the red blood cell (RBC) DHA level.

### Claim 7 (depends on 6)

The method according to claim 6 wherein the step of analysing the blood sample for a red blood cell (RBC) DHA level uses an assessment of dried blood spot (DBS)DHA by a comparison of determined relative quantity of DHA fatty acid to the other 21 fatty acids wherein the sum of the fatty acids constitutes the total fatty acid content of the blood, and each individual fatty acid was expressed as a percent of the total.

### Claim 8 (depends on 6)

The method according to claim 6, wherein the other 24 fatty acids are identified (by class): saturated (14:0, 16:0, 18:0, 20:0, 22:0 24:0); cis monounsaturated (16:1, 18:1, 20:1, 24:1); cis n-6 polyunsaturated (18:2, 18:3, 20:2, 20:3, 20:4, 22:4, 22:5); cis n-3 polyunsaturated (18:3, 20:5, 22:5, 22:6).

### Claim 9 (depends on 6)

The method according to claim 6, wherein the DHA content of the dried blood spot is calculated as the area counts for DHA (22:6) divided by the total area counts for all 24 fatty acids, wherein DHA is expressed as a percent.

### Claim 10 (depends on 7)

The method according to claim 7 wherein the DHA percent from the dried blood spot analysis can be converted to the RBC DHA equivalent using the following equation:
a ratio of the (DBS) DHA level to provide the red blood cell (RBC) DHA level according to:
Prenatal(RBC)DHA=dried blood spot(DBS)DHA×1.2844+0.01
with an error margin of +/−0.01
at a confidence level r=0.95

### Claim 11 (depends on 10)

The method according to claim 10 wherein a DHA level of less than about 5% by the third trimester of pregnancy indicates an increased risk for preterm birth.

### Claim 12 (depends on 11)

The method according to claim 11 wherein the step of adapting includes:
a. addition of a determined quantity and portions of DHA enhancing foods in the diet;
b. addition of a determined quantity and dosages of DHA enhancing substances;
wherein the determined additions are commensurate with expected raising of the assessed DHA level of Prenatal (RBC)DHA to a level of about or greater than 5% by the third trimester of pregnancy.

### Claim 13 (depends on 3)

The method according to claim 3 wherein the step of monitoring the DHA levels in a pregnant woman are conducted at:
a. one stage in the pregnancy term prior to the third trimester; or
b. spaced different stages in the pregnancy term including:
i. about 2-3 months apart;
ii. within the end of the first or the start of the second trimester and at the start of the third trimester
c. prior to becoming pregnant for the purpose of optimizing DHA levels for a wanted future pregnancy

### Claim 14

A method of treating a pregnant woman of a deficiency of docosahexaenoic acid (DHA) by the step of:
a. providing determined addition of quantity and portions of DHA enhancing foods in the diet; and/or addition of a determined quantity and dosages of DHA enhancing substances;
wherein the determined additions are commensurate with assessed prenatal docosahexaenoic acid (DHA) levels and an individual metabolic effectiveness of the additions so as to reach or extend above a level of about or greater than 5% by the third trimester of pregnancy.

### Claim 15 (depends on 14)

The method of treating a pregnant woman according to claim 14 including the step of:
a. monitoring of the individual effectiveness of the additions determined by
i. the monitoring of assessed prenatal docosahexaenoic acid (DHA) levels at spaced different stages in the pregnancy term including within the first or second trimester and
ii. at the start of the third trimester to review, and
b. adjusting the determined addition of quantity and portions of DHA enhancing foods in the diet; and/or addition of a determined quantity and dosages of DHA enhancing substances as an aid to reach or extend above a level of about or greater than 5% by the third trimester of pregnancy
wherein a DHA level of about or greater than about 5% by the third trimester of pregnancy provides a decreased risk for preterm birth.

### Claim 16

A method for measuring and managing DHA levels in a pregnant woman to substantially reduce risk of spontaneous preterm birth, the method comprising:
a. determining the blood level of DHA in the pregnant woman at or about the end of the first trimester or beginning of the second trimester (10-20 weeks gestation), the DHA level being a first comparator;
b. determining level of DHA in at least one pregnant subject at least one predetermined period, wherein the at least one pregnant subject having achieved a term pregnancy, and wherein the level of DHA at the at least one predetermined period being at least a second comparator;
c. comparing the level of DHA in the first and at least second comparator;
d. wherein when the difference between the first and the at least second comparator is greater than a predetermined value, administering to the pregnant female subject a therapeutically effective amount of DHA to substantially reduce pathology relating to spontaneous preterm birth and its adverse effects.

### Claim 17 (depends on 16)

The method of claim 16 wherein the first comparator is repeated over the term of the pregnancy at regular spaced intervals and compared with the at least second comparator to assess and regulate the levels of DHA and determine treatment regimen to elevate and maintain DHA levels.

### Claim 18 (depends on 16)

The method of claim 16 wherein the process of testing blood levels of DHA and adapting intake based on the results is done any time before and during pregnancy as well as postpartum for the other benefits that DHA provides for the mother and infant.

### Claim 19 (depends on 16)

The method of claim 16 wherein the DHA analysis of blood uses a dried blood spot (DBS) to provide a (DBS) DHA level to assess the red blood cell (RBC) DHA level, wherein the dried blood spot (DBS) analysis has an improved viable term for assessment than a direct red blood cell (RBC) DHA.

### Claim 20 (depends on 19)

The method according to claim 19 wherein the improved viable term for assessment using the dried blood spot (DBS) analysis is improved over a direct red blood cell (RBC) DHA by:
a. Extended available assessment time;
b. Reduced temperature degradation;
c. Lessening of temperature control.
